Nomura K, Fujimoto Y, Kanbayashi Y, Ikawa K, Taniwaki M
Department of Hematology and Oncology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kamigyo-ku, Kyoto, Japan.
Eur J Clin Microbiol Infect Dis. 2008 Nov;27(11):1141-3. doi: 10.1007/s10096-008-0543-1. Epub 2008 Jun 18.
Voriconazole has been shown to be safe and effective for fungal infection. However, its population pharmacokinetics for patients with hematological malignancies remains unknown. We performed a population pharmacokinetics study of nine hematological patients with 36 points samples. We approximated the drug concentration curve using a linear one-compartment model. The distribution of volume (Vd), elimination rate constant, and clearance (CL) were 68.7 L, 0.163 h(-1), and 11.2 L/h, respectively. By coincidence, our study has verified that the current administration is enough to treat fungus infections by using Monte Carlo simulation. Our data demonstrated that the current administration method is appropriate and effective. Our results may prove to be useful as a basic reference for the clinical usage of voriconazole.
伏立康唑已被证明对真菌感染安全有效。然而,其在血液系统恶性肿瘤患者中的群体药代动力学仍不清楚。我们对9例血液系统患者的36个样本进行了群体药代动力学研究。我们使用线性单室模型来近似药物浓度曲线。分布容积(Vd)、消除速率常数和清除率(CL)分别为68.7 L、0.163 h⁻¹和11.2 L/h。巧合的是,我们的研究通过蒙特卡罗模拟验证了当前给药剂量足以治疗真菌感染。我们的数据表明,当前的给药方法是合适且有效的。我们的结果可能会成为伏立康唑临床应用的有用基础参考。